Q-omics provides the consensus-scored CBLN3 profile across patient tissues and cancer cell-line models. CBLN3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CBLN3 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, CBLN3 RNA expression shows 17,704 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where CBLN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBLN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBLN3 survival associations across molecular data types. CBLN3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBLN3 RNA expression–survival associations across cancer types. High CBLN3 expression shows unfavorable associations in KICH, UVM, LGG and KIRP, but favorable associations in SKCM and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CBLN3 RNA expression.
This table summarizes CBLN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CBLN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBLN3 shows lower tumor expression in UCEC, KICH and BLCA and higher tumor expression in KIRC, HNSC and LUAD. The KIRC box plot shows higher CBLN3 RNA expression in tumor versus normal tissue (log2 FC = +1.309, t-test p < 0.001).
This table shows molecular features associated with CBLN3 in patient tissues and cancer cell lines. In patient samples, CBLN3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CBLN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
